Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price
ALNYStock
$231.83−51.81%52W
Market Cap$31.02B
P/E98.87x
PEG Ratio0.30
Div yield—
Beta0.37
ALNY Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-41.60%
Price vs S&P 500 (4W)-3.79%
PEG Ratio0.30
VGM Score54.13
P/E Ratio (Annual)98.87x
ALNY Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $2.14 | $1.84 | -14.21%(-$0.30) | |
| Q1 2026 | $1.47 | $1.99 | +35.30%(+$0.52) | |
| Q4 2025 | $1.50 | $1.25 | -16.50%(-$0.25) | |
| Q3 2025 | $1.75 | $2.90 | +66.12%(+$1.15) | |
| Q2 2025 | $0.15 | $0.32 | +119.58%(+$0.17) |
ALNY Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.95
3.97
4.00
4.00
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
ALNYAlnylam Pharmaceuticals, Inc. | D | A | C | 6.5x | 95.1% | 79.7% | — | $231.83 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapeutics with five FDA-approved drugs generating revenue across rare genetic diseases and cardio-metabolic indications. The company has an expanding pipeline in genetic medicines, hepatic infectious diseases, and CNS/ocular diseases, with multiple programs in clinical development. Partnership upfront fees and upcoming milestone and royalty payments from collaborations provide additional cash generation and revenue diversification beyond its commercial portfolio.